Literature DB >> 30780109

The effects of Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract on X-irradiation-induced myocardial fibrosis in rats.

Chengxu Ma1, Zhaoyuan Fu2, Huan Guo3, Huiping Wei2, Xinke Zhao2, Yingdong Li4.   

Abstract

Radix Angelica Sinensis and Radix Hedysari are traditional Chinese medicines that are used for preventing and treating various diseases. This study aimed to investigate the effect and possible underlying mechanisms of Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract (RAS-RH) on X-irradiation-induced cardiac fibrosis in rats. Our data demonstrated that (a) a single dose of total body irradiation (TBI) at 8 Gy resulted in cardiac fibrosis, whereas the control hearts exhibited less collagen and fibrosis. RAS-RH mitigated these morphological injuries. (b) TBI resulted in an increase in the serum levels of transforming growth factor β1 (TGF-β1) and troponin-I (TnI). RAS-RH inhibited the release of TBI-induced serum TGF-β1 and the TnI levels. (c) TBI inhibited the apoptosis of primary rat cardiac fibroblasts, whereas RAS-RH induced the apoptosis of primary rat cardiac fibroblasts after X- irradiation. (d) TBI resulted in an increase in the expression of osteopontin (OPN), c-fos, c-jun, miRNA-21 and collagen1α (COL1α) in primary rat cardiac fibroblasts, and RAS-RH mitigated the TBI-induced increased expression of OPN, c-jun, miRNA-21 and COL1α. In conclusion, these results demonstrate that RAS-RH exerts antifibrotic effects possibly through inducing the apoptosis of fibroblasts, inhibiting the release of serum TGF-β1, reducing the levels of serum TnI and reducing the expression of OPN, c-jun, miRNA-21 and COL1α. Therefore, RAS-RH may potentially be developed as a medical countermeasure for the mitigation of radiation-induced myocardial fibrosis.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  MicroRNA-21; Osteopontin; Radiation-induced myocardial fibrosis; Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract; Transcription factor AP-1

Mesh:

Substances:

Year:  2019        PMID: 30780109     DOI: 10.1016/j.biopha.2019.01.057

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

Review 1.  Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis.

Authors:  Chunzhen Ren; Kai Liu; Xinke Zhao; Huan Guo; Yali Luo; Juan Chang; Xiang Gao; Xinfang Lv; Xiaodong Zhi; Xue Wu; Hugang Jiang; Qilin Chen; Yingdong Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

2.  New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis.

Authors:  Gizele Cabral Costa; Tadeu Lima Montagnoli; Jaqueline Soares Da Silva; Allan Kardec Nogueira de Alencar; Luis Eduardo Reina Gamba; Bryelle Eccard Oliveira Alves; Marina Moraes Carvalho da Silva; Margarete Manhães Trachez; José Hamilton M do Nascimento; Pedro Moreno Pimentel-Coelho; Rosália Mendez-Otero; Lidia Moreira Lima; Eliezer J Barreiro; Roberto Takashi Sudo; Gisele Zapata-Sudo
Journal:  Drug Des Devel Ther       Date:  2020-08-17       Impact factor: 4.162

3.  Radix Angelica Sinensis and Radix Hedysari Ultrafiltration Extract Protects against X-Irradiation-Induced Cardiac Fibrosis in Rats.

Authors:  Chengxu Ma; Xinke Zhao; Juan Chang; Huan Guo; Huiping Wei; Zhaoyuan Fu; Yingdong Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-21       Impact factor: 2.629

4.  miR-21 is upregulated, promoting fibrosis and blocking G2/M in irradiated rat cardiac fibroblasts.

Authors:  Huan Guo; Xinke Zhao; Haixiang Su; Chengxu Ma; Kai Liu; Shanshan Kong; Kedan Liu; Haining Li; Juan Chang; Tao Wang; Hongyun Guo; Huiping Wei; Zhaoyuan Fu; Xinfang Lv; Yingdong Li
Journal:  PeerJ       Date:  2020-12-10       Impact factor: 2.984

5.  Ultrafiltration Extract of Radix Angelica Sinensis and Radix Hedysari Attenuates Risk of Low-Dose X-Ray Radiation-Induced Myocardial Fibrosis In Vitro.

Authors:  Juan Chang; Chengxu Ma; Huan Guo; Haiqiong Ran; Guolian Chen; Yingdong Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-28       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.